[123I]β-CIT SPECT imaging demonstrates reduced density of striatal dopamine transporters in Parkinson's disease and multiple system atrophy
Article first published online: 7 NOV 2001
Copyright © 2001 Movement Disorder Society
Volume 16, Issue 6, pages 1023–1032, November 2001
How to Cite
Varrone, A., Marek, K. L., Jennings, D., Innis, R. B. and Seibyl, J. P. (2001), [123I]β-CIT SPECT imaging demonstrates reduced density of striatal dopamine transporters in Parkinson's disease and multiple system atrophy. Mov. Disord., 16: 1023–1032. doi: 10.1002/mds.1256
- Issue published online: 29 NOV 2001
- Article first published online: 7 NOV 2001
- Manuscript Accepted: 6 MAR 2001
- Manuscript Revised: 5 MAR 2001
- Manuscript Received: 23 MAY 2000
- movement disorders;
- substantia nigra;
- basal ganglia;
In vivo imaging of the dopamine transporter (DAT) with single photon emission computed tomography (SPECT) is a quantitative biomarker for Parkinson's disease (PD) onset and severity. This study has examined and compared the loss of striatal DAT in PD and multiple system atrophy (MSA) using [123I]β-CIT SPECT imaging.
One hundred and eighty-three patients (157 PD and 26 MSA) were studied. Clinical rating scales (Hoehn and Yahr stage and Unified Parkinson's Disease Rating Scale [UPDRS] scores) demonstrated that the MSA patients were more severely impaired than the PD patients. The striatal [123I]β-CIT SPECT uptake was markedly reduced in both the PD and MSA groups. In addition, MSA patients showed more symmetric DAT loss compared with the PD patients, consistent with the more symmetric clinical motor dysfunction observed in MSA. While the loss of DAT was significantly reduced in all regions in both MSA and PD, comparison of the relative loss of the DAT did not significantly improve diagnostic accuracy in distinguishing between PD and MSA. © 2001 Movement Disorder Society.